Assays of type I procollagen domains and collagen fragments: Problems to be solved and future trends

Scandinavian Journal of Clinical and Laboratory Investigation, Supplement

Volumn 57, Issue 227, 1997, Pages 105-113

  Risteli, Juha ^a   Risteli, Leila ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; BIOLOGICAL MARKER; PEPTIDE FRAGMENT; PROCOLLAGEN;

COLLAGEN METABOLISM; CONFERENCE PAPER; HUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CROSS LINKING; PROTEIN DEGRADATION; CHEMISTRY; DIAGNOSIS, MEASUREMENT AND ANALYSIS; REVIEW;

BIOLOGICAL MARKERS; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; PEPTIDE FRAGMENTS; PROCOLLAGEN;

EID: 0030629117     PISSN: 0085591X     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365519709168316     Document Type: Conference Paper

References (26)

1. Eriksen EF, Brixen K, Charles P. New markers of bone metabolism; clinical use in metabolic bone disease. Eur J Endocrinol 1995;132:251-263.
2. Stein GS, Lian JB, Owen TA. Relationship of cell growth to the eegulation of tissue-specific gene expression during osteoblast differentiation. FASEB J 1990;4:3111-3123.
3. Prockop DJ, Kivirikko KI, Tuderman L, Guzman NA. The biosynthesis of collagen and its disorders. New Engl J Med 1979;301:12-23, 77-85.
4. Risteli J, Niemi S, Kauppila S, Melkko J, Risteli L. Collagen propeptides as indicators of collagen assembly. Acta Orthop Scand 1995 (Suppl 266);66:183-188.
5. 2-terminaI propeptides of types I and III procollagen is a physiological function of the scavenger receptor in liver endothelial cells. J Exp Med 1994;179:405-412.
6. Smedsrød B, Melkko J, Risteli L, Risteli J. Circulating carboxyterminal propeptide of type I procollagen is cleared via the mannose receptor in liver endothelial cells. Biochem J 1990;271.345-350.
7. Taubman MB, Goldberg B, Sherr CJ. Radioimmunoassay for human procollagen. Science 1974;186:1115-1117.
8. Melkko J, Niemi S, Risteli L, Risteli J. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 1990;36:1328-1332.
9. Pedersen BJ, Bonde M. Purification of human procollagen type I carboxyl-terminal propeptide cleaved as in vivo from procollagen and used to calibrate a radioimmunoassay of the propeptide. Clin Chem 1994;40:811-816.
10. Ebeling PR, Peterson JM, Riggs BL. Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases. J Bone Miner Res 1992;7:1243-1250.
11. Linkhart SH, Linkhart TA, Taylor AK, Wergedal JE, Bettica P, Baylink DJ. Synthetic peptide-based immunoassay for amino-terminal propeptide of type I procollagen: application for evaluation of bone formation. Clin Chem 1993;39:2254-2260.
12. Rasmussen HB, Teisner B, Grma J, Brixen K, Yde-Andersen E, Bollerslev J. Serum levels of fetal antigen 2 in hyperthyroidism and primary hyperparathyroidism. APMIS 1992;100:894-900.
13. Price KM, Silman R, Armstrong P, Grudzinskas JG. Development of a radioimmunoassay for fetal antigen 2. Clin Chim Acta 1994;224:95-102.
14. Melkko J, Kauppila S, Niemi S, Risteli L, Haukipuro K, Jukkola A, Risteli J. Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem 1996;42:947-954.
15. Toivonen J, Tähtelä R, Laitinen K, Risteli J, Välimäki MJ. Markers of bone turnover in patients with differentiated thyroid cancer on and off thyroxine suppressive therapy. Manuscript, submitted for publication.
16. Sharp CA, Evans SF, Risteli L, Risteli J, Worsfold M, Davie MWJ. Effects of low and conventional dose transcutaneous HRT over 2 years on bone metabolism in younger and older postmenopausal women. Eur J Clin Invest 1996;26:763-771.
17. Sharp CA, Davie MWJ, Worsfold M, Risteli L, Risteli J. Discrepant blood concentrations of type I procollagen propeptides in active Paget disease of bone. Clin Chem 1996;42:1121-1122.
18. Eyre DR, Paz MA, Gallop PM. Cross-linking in collagen and elastin. Ann Rev Biochem 194;53:717-748.
19. Risteli J, Eriksen H, Risteli L, Mansell JP, Bailey AJ. Pyrrolic cross-links are as abundant in human bone type I collagen as pyridinolines. J Bone Min Res 1994;9:S186
20. Hanson DA, Eyre DR. Molecular site specificity of pyridinoline and pyrrole cross-links in type I collagen of human bone. J Biol Chem 1996;271:26508-26516.
21. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxyterminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 1993;39:635-640.
22. Sassi M-L, Eriksen H, Niemi S, Mansell J, Risteli L, Risteli J. Immunochemical characterization of the assay for the human carboxyterminal telopeptide of type I collagen (ICTP) by comparison with the corresponding bovine antigen. Manuscript, submitted for publication.
23. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 1994;40:2022-2025.
24. Hanson DA, Weis MAE, Bollen A-M, Maslan SL, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992;7:1251-1258.
25. Blumsohn AC, Naylor K, Eastell R. Effect of light and -irridation on pyridinolines and telopeptide of type I collagen in urine. ClinChem 1995;41:1195-1197.
26. Robins SP. Collagen crosslinks in metabolic bone diseases. Acta Ortop Scan 1995;66(Suppl 266):171-175.